Physician profile
Amber Renee Hoberg
NPI 1003122532
$1,857,700.69
in general payments reported to CMS, 2019-2025
26 companies · $439K in 2025
The $439K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189K · 2022: $343K · 2023: $427K · 2024: $460K · 2025: $439K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $842K · Consulting Fee: $222K · Travel and Lodging: $186K · Food and Beverage: $40K · Honoraria: $35K · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $842,218.19 |
| Consulting Fee | $221,680.40 |
| Travel and Lodging | $186,008.97 |
| Food and Beverage | $40,269.23 |
| Honoraria | $35,330.50 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $923,175.75 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285,397.11 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $243,860.09 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $157,943.75 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $83,551.71 | 2022-2025 | Auvelity, Sunosi |
| Acadia Pharmaceuticals INC | $45,642.77 | 2021-2025 | Nuplazid |
| Alkermes, INC. | $34,181.15 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,238.03 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $17,004.97 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Avanir Pharmaceuticals, INC. | $9,340.79 | 2021-2022 | |
| Indivior INC. | $8,493.88 | 2022-2024 | Perseris |
| Bioxcel Therapeutics, INC. | $6,247.78 | 2023 | Igalmi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,661.05 | 2023-2025 | Abilify Maintena, Rexulti |
| Biogen, INC. | $3,269.47 | 2023-2024 | |
| Abbvie INC. | $628.97 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $316.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $209.97 | 2022-2025 | Invega Sustenna |
| Uswm, LLC | $133.26 | 2021 | |
| Janssen Scientific Affairs, LLC | $110.21 | 2025 | Invega Trinza, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $85.10 | 2025 | Fanapt |
| Lundbeck LLC | $50.73 | 2023 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $47.31 | 2023-2024 | Qelbree, Qelbree |
| Corium, LLC | $44.36 | 2023 | Adlarity |
| Sage Therapeutics, LLC | $26.97 | 2023 | |
| Mylan Specialty L.P. | $23.45 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Hoberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.